Join the club for FREE to access the whole archive and other member benefits.

Scott Gottlieb

American physician and investor.

Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner he was a clinical assistant professor at New York University School of Medicine, the FDA Deputy Commissioner for Medical and Scientific Affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, and a senior official at the Centers for Medicare and Medicaid Services. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.

Visit website: http://www.scottgottlieb.com/

 scottgottliebMD

 scottgottliebmd

 ScottGottliebMD

See also: Company Food and Drug Administration (FDA) - Ensuring safety of drugs, medical supplies and food which is used daily.

Details last updated 13-Dec-2019

Scott Gottlieb News

35 reported cases of seizures following e-cigarette use

35 reported cases of seizures following e-cigarette use

Independent - 03-Apr-2019

FDA stresses it is not clear whether e-cigarettes have triggered seizures in dozens of users

Ambrosia ceases young blood plasma treatment

Ambrosia ceases young blood plasma treatment

CNN - 19-Feb-2019

Only 2 months after starting. Calling it a medical treatment may be contravened FDA guidance.

Drug approved as alternative method to CRISPR

Drug approved as alternative method to CRISPR

Singularity Hub - 21-Aug-2018

Patisiran is a new drug capable of silencing genes based on RNA interference technology

FDA Target Rogue Gene Therapy Clinics

FDA Target Rogue Gene Therapy Clinics

New York Times - 16-Nov-2017

FDA issued new guidelines for expedited review of stem cell and gene therapies. Will crack down ...

FDA Cracks Down on Stem Cell Clinics

FDA Cracks Down on Stem Cell Clinics

New York Times - 28-Aug-2017

The F.D.A.  reported actions against two large stem cell clinics and a biotech company calling th...